Cytosorbents Corp (CTS) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Cytosorbents Corporation is a medical device company focused on blood purification technologies, primarily through its lead product, CytoSorb, which is approved in the EU and distributed in 76 countries. The company is also developing DrugSorb-ATR for the U.S. market, for which it submitted a De Novo application to the FDA in September 2024 (accepted for review in October 2024).
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $9.39 million | $8.81 million | $29.07 million | $27.68 million |
| Product Sales | $8.61 million | $7.75 million | $26.44 million | $23.74 million |
| Grant Income | $0.78 million | $1.06 million | $2.63 million | $3.94 million |
| Gross Profit | $5.28 million | $5.61 million | $18.35 million | $17.08 million |
| Net Loss | $(2.33) million | $(9.19) million | $(12.84) million | $(22.67) million |
| Cash & Equivalents | $5.69 million | $14.13 million (Dec '23) | Total Cash (incl. restricted): $12.17 million | |
| Restricted Cash | $6.48 million | $1.48 million (Dec '23) | Primarily held for debt covenants | |
| Long-Term Debt | $13.81 million | $2.54 million (Dec '23) | Principal: $15.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 7% QoQ and 5% YoY. Product sales grew 11% YoY, driven by a 21% increase in direct sales, partially offset by a 1% decrease in distributor sales.
- Grant Income Decline: Grant income decreased 26% in Q3 and 33% YTD compared to the prior year, attributed to the completion of several government grants in 2023.
- Improved Profitability: Net loss narrowed significantly to $2.33 million in Q3 2024 from $9.19 million in Q3 2023. This improvement was driven by a $2.65 million gain on foreign currency transactions (due to Euro appreciation) and a 51% reduction in R&D expenses following the completion of the STAR-T clinical trial.
- Debt Financing: In June 2024, the company secured a $20 million facility with Avenue Capital Group. $15 million was drawn (with $5 million restricted), replacing prior Bridge Bank debt. This increased interest expense significantly but provided necessary liquidity.
- Margin Pressure: Product gross margins decreased to 61% in Q3 2024 from 72% in Q3 2023 due to a temporary production slowdown and manufacturing issues.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. Unrestricted cash ($5.7 million) is not expected to fund operations beyond the next 12 months without additional capital.
- Liquidity Milestones: The company is pursuing milestones under its Avenue Capital debt facility to unlock up to $10 million in restricted cash. These include FDA acceptance of the DrugSorb-ATR application (achieved Oct 2024) and raising $3–$5 million in equity.
- Regulatory Progress: The DrugSorb-ATR De Novo application was accepted by the FDA in October 2024. The company also received MDSAP certification and submitted a license application to Health Canada in November 2024.
- Cost Management: The company continues to implement cost-saving initiatives, including headcount reductions and reduced clinical trial spending.
- Risks: Key risks include the inability to raise additional capital, failure to achieve debt milestones, and the outcome of ongoing litigation (a former employee filed a CEPA complaint in March 2024).
Investor Verification Checklist
- Cash Runway: Verify the timeline for unlocking the $5 million restricted cash tranche and the status of the equity raise required to release the remaining funds.
- Production Capacity: Confirm resolution of the Q3 manufacturing issues and the impact on future gross margins.
- Grant Pipeline: Assess the $3.2 million in remaining revenue on open grant contracts and the sustainability of this revenue stream as current grants conclude.
- Debt Covenants: Review the specific terms of the Avenue Capital agreement regarding interest rates (Prime + 5% or 13.5%) and prepayment penalties.
- Regulatory Timeline: Monitor the FDA review timeline for the DrugSorb-ATR De Novo application and potential approval dates.